Latest news with #ImricorMedicalSystems
Yahoo
26-05-2025
- Business
- Yahoo
Institutions own 32% of Imricor Medical Systems, Inc. (ASX:IMR) shares but retail investors control 51% of the company
The considerable ownership by retail investors in Imricor Medical Systems indicates that they collectively have a greater say in management and business strategy The top 20 shareholders own 49% of the company Institutions own 32% of Imricor Medical Systems Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To get a sense of who is truly in control of Imricor Medical Systems, Inc. (ASX:IMR), it is important to understand the ownership structure of the business. We can see that retail investors own the lion's share in the company with 51% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Meanwhile, institutions make up 32% of the company's shareholders. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. In the chart below, we zoom in on the different ownership groups of Imricor Medical Systems. View our latest analysis for Imricor Medical Systems Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in Imricor Medical Systems. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Imricor Medical Systems' historic earnings and revenue below, but keep in mind there's always more to the story. Hedge funds don't have many shares in Imricor Medical Systems. Looking at our data, we can see that the largest shareholder is Challenger Limited with 16% of shares outstanding. In comparison, the second and third largest shareholders hold about 6.9% and 4.2% of the stock. In addition, we found that Steven Wedan, the CEO has 1.9% of the shares allocated to their name. Our studies suggest that the top 20 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. We can report that insiders do own shares in Imricor Medical Systems, Inc.. In their own names, insiders own AU$37m worth of stock in the AU$414m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling. The general public, who are usually individual investors, hold a substantial 51% stake in Imricor Medical Systems, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions. We can see that Private Companies own 4.9%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company. Public companies currently own 3.1% of Imricor Medical Systems stock. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further. It's always worth thinking about the different groups who own shares in a company. But to understand Imricor Medical Systems better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Imricor Medical Systems you should know about. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Web Release
24-04-2025
- Health
- Web Release
Imricor Commences VISABL-VT Trial
By Editor_wr On Apr 24, 2025 Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that it has commenced the VISABL-VT clinical trial by completing the first-in-human ventricular ablation guided by real-time MRI with the Company's NorthStar Mapping System. The procedure was performed by the team at the Amsterdam University Medical Centre (AUMC), ranked in 2025 by Newsweek as the best hospital in The Netherlands, and in the top 35 worldwide. The procedure marked several world firsts. It was the first ventricular ablation to be guided by real-time MRI, and it was the first left-sided ablation to be performed under real-time MRI guidance. The patient was treated for right-sided and left-sided premature ventricular complexes (PVCs). 'During ablation, MRI-images provide a better view of the anatomy of the heart and the instruments used for treatment, but also of the changes made to the treated cardiac tissue. Unlike X-ray images, the entire area surrounding the heart can be seen, including the blood vessels and valves. And the MRI offers the opportunity during the procedure to visualize the effects of the treatment on the myocardial tissue,' says Marco Götte, imaging cardiologist at Amsterdam UMC, initiator and project leader of the cardiac intervention MRI research program. Amsterdam UMC has a long history with the development of MRI-guided cardiac interventions, with numerous firsts and this is yet another an important milestone. 'The patient is doing well; the procedure went according to plan and the arrhythmia has been eliminated. We are therefore extremely proud that with our years of preparation, we have now reached the point where we are the first in the world to be able to treat complex forms of cardiac arrhythmias in an MRI scanner,' says Cor Allaart, Professor of Electrophysiology and cardiologist at Amsterdam UMC. Imricor's Chair and CEO, Steve Wedan, commented, 'We formed Imricor in 2006 with the goal of delivering MRI-compatible catheters and systems that would enable real-time MRI guidance of complex ventricular and atrial ablation procedures, where the power of MRI has the potential to deliver better, faster, safer, and less expensive treatment for patients suffering from irregular heartbeats. This achievement is a huge milestone for both Imricor and Amsterdam UMC.' Imricor Commences VISABL-VT Trial Comments are closed.
Business Insider
24-04-2025
- Business
- Business Insider
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) Receives a Buy from Morgans
Morgans analyst Scott Power maintained a Buy rating on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR – Research Report) today and set a price target of A$2.28. The company's shares closed today at A$1.51. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. According to TipRanks, Power is an analyst with an average return of -4.8% and a 35.34% success rate. Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an analyst consensus of Hold. The company has a one-year high of A$1.71 and a one-year low of A$0.41. Currently, Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an average volume of 379.1K.
